Storm Therapeutics raised $56 million in a Series C financing to support Phase II development of STC-15, an RNA enzyme inhibitor targeting METTL3. The company said it has enrolled the first patient in its sarcoma trial and plans to report Phase II results across selected indications. The financing also positions Storm to pursue accelerated pathways if efficacy data support clinical benefit. STC-15’s premise is that METTL3-driven mRNA methylation remains a dependency in certain myo- and liposarcomas where standard targeted options have been limited. The capital injection reinforces a shift toward RNA-modifying enzyme targets as a druggable axis in oncology, particularly for hard-to-treat subtypes.